<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03871920</url>
  </required_header>
  <id_info>
    <org_study_id>SPEQ</org_study_id>
    <nct_id>NCT03871920</nct_id>
  </id_info>
  <brief_title>Psychometric Evaluation of the Short Patient Evaluation Questionnaire</brief_title>
  <official_title>A Prospective Multi Center Prospective Cross-sectional and Longitudinal Study to Evaluate the Psychometric Properties of the Short Patient Evaluation Questionnaire</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nanco van der Maas</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University Hospital Inselspital, Berne</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>HES-SO Valais-Wallis</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Bern</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Institut fuer Physiotherapieforschung</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      It is important for physiotherapy in general and for the individual physio-therapist to
      demonstrate the result of the interventions in physiotherapy. The new short (4 items) generic
      questionnaire Short Patient Evaluation Questionnaire SPEQ was especially developed for use in
      private practices to answer the main questions for evaluation of treatment. This research
      project aims at evaluating the reliability, validity and responsiveness of the SPEQ and at
      providing an estimate for Minimal Important Difference MID that may be used as threshold for
      clinical relevant changes.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In this study the investigators evaluate the reliability, validity and responsiveness of the
      SPEQ and providing an estimate for Minimal Important Difference MID. They will use a
      longitudinal multicenter design with an adequate sample size of n=250 for validity and n=80
      for reliability evaluation. Private practices and the Department of Physiotherapy of the
      Inselspital, Bern University Hospital, will participate in the study.

      Reliability will be evaluated in a test-retest setting and with ordinal alpha. The SPEQ will
      be compared to the Euroqual-5-Dimensions-5-Levels (EQ-5D-5L), Short Form 12 (SF-12) and
      Patient Satisfaction Questionnaire (PSQ) to evaluate the validity. Responsiveness will be
      evaluated using a criterion validity approach and hypothesis testing of the correlation
      between SPEQ and the other questionnaires. In addition, the investigators will calculate ES,
      Standardized Response Mean (SRM), Modified SRM (MSRM) and relative efficiency between SPEQ
      and the criterions. For MID estimates, they use a combined anchor and distribution based
      approach. The anchors for the items are provided by the T0- and T1-questionnaire.

      Patients will be recruited by the treating physiotherapists and provide written informed
      consent. At baseline, they will complete the T0-questionnaire, SF-12 and EQ-5D-5L. At the end
      of treatment or after 6 month of treatment for persons in long term treatment, the patients
      will fill out SPEQ, the T1-questionnaire, SF-12, EQ-5D-5L, and the PSQ. Two to seven days
      after the second test series, a subset of patients(n=80) will be asked to answer the SPEQ
      questions again by telephone.

      Descriptive statistics will describe missing data, distribution of data over scale levels,
      frequency, floor and ceiling effects. Scaling will be tested by comparing pearson and
      spearman correlations and effect size (ES) for ordinal data and for metric data. Independence
      will be evaluated with the Mann-Whitney U test. The assumptions for building a sum of score
      will be evaluated comparing and assessing the spearman correlations and a categorical
      principle component analysis of the matrix of the 4 items of the SPEQ.

      The reliability will be evaluated. Correlations between the SPEQ and the criterions EQ-5D-5L,
      SF-12 and PSQ will demonstrate validity.

      Responsiveness will be evaluated analyzing the correlations between SPEQ and criterion and
      hypothesis testing of change of scores (Cosmin). Furthermore we will calculate the several
      traditional statistics; Effect Size, Standardized Response Mean, Modified Standardized
      Response Mean and relative efficiency between SPEQ and the criterion; distribution based
      Minimal Important Change estimates will be calculated with 0.5 Standard Deviation, Standard
      Error Measurement and Minimal Detectable Change at the 95% confidence interval; the mean
      between T0 and T1 values are anchor-based MID estimates. The range of anchor and distribution
      based MIC estimates will be analysed by Receiver Operating Characteristics curves. The result
      of the analysis provides an estimate that will be compared to the MID estimate of the
      criterion validity approach. Finally the threshold for clinical relevant change for the items
      and the sum of scores of the SPEQ will be determined.

      The investigators expect the SPEQ to be a reliable, valid and responsive patient rated
      outcome assessment that can be used in the evaluation of the results of physiotherapy
      treatment.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">June 1, 2019</start_date>
  <completion_date type="Anticipated">October 1, 2019</completion_date>
  <primary_completion_date type="Anticipated">June 1, 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Test Retest reliability of SPEQ</measure>
    <time_frame>up to 30 weeks</time_frame>
    <description>Intra-Class Correlation coefficient (using a two way random effects model)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Accuracy of the SPEQ</measure>
    <time_frame>up to 30 weeks</time_frame>
    <description>analysis of accuracy of SPEQ to detect patients who changed in transition question with ROC analysis</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Criterion Validity</measure>
    <time_frame>up to 30 weeks</time_frame>
    <description>The validity will be assessed using hypothesis testing of correlations (between SPEQ and existing previously validated measures). The SPEQ has a sufficient criterion validity, if these correlations are at least moderate (rho&gt;0.5)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Inner consistancy</measure>
    <time_frame>up to 30 weeks</time_frame>
    <description>The inner consistency will be calculated with ordinal alpha.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Construct validity of the SPEQ</measure>
    <time_frame>up to 30 weeks</time_frame>
    <description>Categorial principle component analysis of SPEQ will be performed to asses the construct validity of the SPEQ.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Responsiveness of the SPEQ</measure>
    <time_frame>up to 30 weeks</time_frame>
    <description>Sensitivity to change will be evaluated using Effect Size, Standardized Mean, Modified standardized Mean and Relative efficiency.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Validity of the SPEQ as assessed using Spearman correlations with scores of other previously validated measures</measure>
    <time_frame>up to 30 weeks</time_frame>
    <description>The validity of the SPEQ was determined by calculating Spearman correlations between SPEQ and scores of previously validated measures (EQ-5D-5L, SF-12 and SPQ). Scores &gt;0.6 were considered indicative of high validity.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Smallest sum of the proportions of misclassification</measure>
    <time_frame>up to 30 weeks</time_frame>
    <description>By defining a cut-off value at the smallest sum of the proportions of misclassification, the investigators will define Minimal Important Difference</description>
  </other_outcome>
  <other_outcome>
    <measure>Distribution based Minimal Important Difference</measure>
    <time_frame>up to 30 weeks</time_frame>
    <description>MID is defined for all items and the sum of item scores as 0.5 Standard Deviation, Standard Error Measurement and Minimal Detectable Change at the 95% confidence interval</description>
  </other_outcome>
  <other_outcome>
    <measure>Anchor based Minimal Important Difference</measure>
    <time_frame>up to 30 weeks</time_frame>
    <description>MID is defined for item 2, 3 and the sum of items scores as the average change between T1 and T2 for the subset of patients with a minimal change as determined by the transition question.</description>
  </other_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">250</enrollment>
  <condition>Patient Reported Outcomes</condition>
  <arm_group>
    <arm_group_label>intervention</arm_group_label>
    <description>any kind of condition treated by physiotherapists, physical therapy treatment is chosen by treating physiotherapist</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>physical therapy treatment</intervention_name>
    <description>any treatment chosen by treating physiotherapist</description>
    <arm_group_label>intervention</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        The study population will consist of the regular patient in full age in physical therapy
        treatment without a grave other health problems, that may interfere with the result of the
        treatment with physiotherapy
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion criteria

          -  Persons older than 18 years, that are in physical therapy treatment.

          -  Persons must be able to read and understand German.

        Exclusion criteria

          -  Grave cognitive changes

          -  Bedridden patients

          -  Grave comorbidities that may interfere with the treatment with physical therapy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nico van der Maas</last_name>
    <role>Principal Investigator</role>
    <affiliation>Institut f√ºr Physiotherapieforschung gmbh, Biel, Switzerland</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Martin Verra, PHD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Institute of physiotherapy, Insel university hospital, Bern, Switzerland</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Roger Hilfiger, MSc.</last_name>
    <role>Principal Investigator</role>
    <affiliation>HES-SO Valais/Wallis, Leukerbad, Switzerland</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Angela Balsimann Schwarz, MSc.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Bern university of applied sciences, Health professions</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Nico van der Maas</last_name>
    <phone>+41764373695</phone>
    <email>ipforschung@sunrise.ch</email>
  </overall_contact>
  <verification_date>March 2019</verification_date>
  <study_first_submitted>August 15, 2017</study_first_submitted>
  <study_first_submitted_qc>March 9, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">March 12, 2019</study_first_posted>
  <last_update_submitted>March 9, 2019</last_update_submitted>
  <last_update_submitted_qc>March 9, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">March 12, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Institut fuer Physiotherapieforschung</investigator_affiliation>
    <investigator_full_name>Nanco van der Maas</investigator_full_name>
    <investigator_title>Principle investigator</investigator_title>
  </responsible_party>
  <keyword>Physiotherapy</keyword>
  <keyword>outcomes</keyword>
  <keyword>therapy quality</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

